Autoimmune Drugs Market Size to grow by USD 33218.8 million between 2024-2028
According to a research report “ Autoimmune Drugs Market” by Therapy Area (Rheumatoid arthritis, Multiple sclerosis, Psoriasis, Inflammatory bowel disease, Others) Distribution Channel (Hospital, Pharmacy, Drug store/Retail pharmacy, Online) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 33218.8 million, at a CAGR of 6.78% during the forecast period. Autoimmune diseases, afflicting over 80 identified conditions, impact a significant global population segment. Notable diseases include rheumatoid arthritis, psoriasis, type I diabetes, inflammatory bowel diseases (IBD), ulcerative colitis, and lupus. In the US, approximately 3% of the population, equating to millions, grapple with these disorders. Biopharmaceutical companies in the Americas are investing substantially in research and development (R&D) for autoimmune drugs to cater to this patient demographic. Over 200 potential biologics and small molecule products are currently in development pipelines..
Browse market data tables, figures, and in-depth TOC on “Autoimmune Drugs Market” by Therapy Area (Rheumatoid arthritis, Multiple sclerosis, Psoriasis, Inflammatory bowel disease, Others) Distribution Channel (Hospital, Pharmacy, Drug store/Retail pharmacy, Online) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Therapy Area, the Rheumatoid arthritis segment is projected to dominate the market size in 2024
In the healthcare industry, autoimmune disorders, particularly rheumatoid arthritis (RA), pose a significant challenge due to their chronic nature and potential for joint deformity and bone erosion. RA is characterized by the immune system's misidentification and attack on the body's own cells, leading to inflammation, pain, and swelling, primarily affecting the joints in the hands and feet. Prevalence rates are notably high in developed nations, including the US, where an increasing number of elderly individuals are being diagnosed. The current treatment landscape for RA includes conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs), small molecule therapeutics, and advanced biologics. Biologics, which target specific proteins involved in the immune response, have demonstrated long-term efficacy and are extensively utilized by rheumatologists globally to manage this debilitating condition.
By Distribution Channel, Hospital segment is expected to hold the largest market size for the year 2024
Autoimmune drugs hold significant market potential within the healthcare sector, particularly in hospitals. Given the substantial demand for these medications in treating patients, hospitals serve as a primary sales channel. Notably, governments' increasing investments in healthcare infrastructure in countries like India and China will fuel market expansion during the forecast period. The burgeoning hospital sector in developing nations, such as India, coupled with government initiatives to enhance healthcare infrastructure, has resulted in a surging demand for autoimmune drugs to address conditions like arthritis, psoriasis, and others. Consequently, the hospital segment of the autoimmune drugs market is poised for robust growth.
North America is forecasted to hold the largest market size by region in 2024
The Autoimmune Drugs Market represents a significant business opportunity, driven by the rising prevalence of autoimmune diseases and the increasing demand for effective treatments. Key players in this market are investing in research and development to launch innovative therapies, while strategic collaborations and acquisitions are shaping the competitive landscape. The market's growth is also fueled by regulatory approvals and expanding indications for existing drugs. Overall, the Autoimmune Drugs Market is poised for robust expansion in the forecast period.
The Autoimmune Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Autoimmune Drugs Market encompasses a range of pharmaceutical products designed to treat various autoimmune diseases, including Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Rheumatoid Arthritis. Key players in this market include Effector T cells and regulatory T cells, which play crucial roles in the immune response. Autoimmune drugs work by targeting specific proteins and pathways, such as Dihydroorotate dehydrogenase, Folic acid, Interferon gamma, and Biosimilars like Certolizumab pegol, Golimumab, Adalimumab, and Etanercept. Immunosuppressants, such as Cyclosporine, Antimalarials, Cyclophosphamide, Azathioprine, Sulfasalazine, Gold compounds, and NSAID therapy (including Aspirin, Willow spp, and Salicylates), are also commonly used. One emerging class of autoimmune drugs is Anti-TNF therapy, which targets the TNF protein to reduce inflammation. These drugs have been effective in treating various autoimmune diseases, including Psoriasis, Ankylosing Spondylitis, and Rheumatoid Arthritis. However, their high cost and potential side effects have led to the development of biosimilars, which offer more affordable alternatives while maintaining similar efficacy.
Market Research Overview
The Autoimmune Drugs Market encompasses a wide range of pharmaceutical products used to treat various autoimmune inflammatory diseases, including plaque psoriasis, ulcerative colitis, Crohn's disease, psoriatic arthritis, juvenile rheumatoid arthritis, and others. These diseases are characterized by the immune system attacking healthy cells and tissues in the body. Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, salicylates from Willow spp, and prostaglandin inhibitors like ibuprofen and naproxen, are commonly used to manage symptoms of inflammation and pain. However, for more severe cases, disease-modifying anti-rheumatic drugs (DMARDs) like Leflunomide, Methotrexate, and D-penicillamine, or biologic agents, are required. Biologic agents, such as Certolizumab pegol, Golimumab, Adalimumab, and Etanercept, target specific molecules involved in the immune response, including TNF-alpha, Lymphotoxin, and Interleukin-1. They employ mechanisms like antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and effector T cell suppression. DMARDs and biologic agents also include immunosuppressants like Cyclosporine, D-penicillamine, Antimalarials, Cyclophosphamide, Azathioprine, and Sulfasalazine, as well as Gold compounds. Interferon gamma and Folic acid are also used in some treatments. Autoimmune diseases like psoriasis, ankylosing spondylitis, inflammatory bowel disease, and rheumatoid arthritis are treated with these drugs, which can inhibit the activity of enzymes like Cyclooxygenase and Dihydroorotate dehydrogenase. Glucocorticoids, such as prednisone, are often used in combination with other therapies to manage symptoms. Biosimilars, which are similar but not identical to original biologic drugs, are increasingly being used due to their cost-effectiveness and improved accessibility. Overall, the Autoimmune Drugs Market is expected to grow significantly due to the increasing prevalence of autoimmune diseases and the development of new, more effective treatments.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
